Key result
Switching to a combination therapy of high-dose ARB, CCB, and hydrochlorothiazide significantly reduced systolic blood pressure from 142 mmHg to 125 mmHg and increased target BP achievement to 72% at 3 months.
Why the study?
Does switching to a triple combination of high-dose ARB, CCB, and HCTZ improve blood pressure control in hypertensive patients inadequately controlled on prior therapies?
Population
32 hypertensive patients in Japan previously treated with high-dose ARB/CCB or middle-dose ARB/CCB/HCTZ for…
Comparison
Switch to combination therapy of high-dose ARB… vs Baseline values.
Design
Cohort
Follow-up
3 months
Authors
Loading...
May support triple therapy in resistant hypertension; hypothesis-generating and requires RCT confirmation.
Observational (n=32)
Open-label
Does switching to a triple combination of high-dose ARB, CCB, and HCTZ improve blood pressure control in hypertensive patients inadequately controlled on prior therapies?
Absolute Event Rate: 125% vs 142%
p-value: p=<0.05
Switching to a triple combination of high-dose ARB, CCB, and HCTZ significantly improves blood pressure control in hypertensive patients inadequately controlled on prior dual or lower-dose triple therapies.
Shiga et al. (2016) conducted an observational in Hypertension (n=32). High-dose ARB (telmisartan), CCB, and hydrochlorothiazide vs. Baseline (previous therapy with H-ARB/CCB or M-ARB/CCB/HCTZ) was evaluated on Systolic blood pressure (p=<0.05). Switching to a combination therapy of high-dose ARB, CCB, and hydrochlorothiazide significantly reduced systolic blood pressure from 142 mmHg to 125 mmHg and increased target BP achievement to 72% at 3 months.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: